MARC DESOLMINIHAC: Open Payments
NPI 1255342952 · NORFOLK, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$771 in 44 payments from 16 companies in 2025. Trend: 2023 $1,402 · 2024 $986 · 2025 $771
Food & beverage: $771
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $192 |
| Vanda Pharmaceuticals Inc. | 4 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $66 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $63 |
| E.R. Squibb & Sons, L.L.C. | 2 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $44 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Alkermes, Inc. | 2 | $38 |
| Lundbeck LLC | 2 | $36 |
| Janssen Pharmaceuticals, Inc | 1 | $24 |
Products named: VRAYLAR, FANAPT, TRINTELLIX, CAPLYTA, COBENFY, REXULTI, AUSTEDO XR, Auvelity.
Industry payments across VA — which companies pay providers there.
